trending Market Intelligence /marketintelligence/en/news-insights/trending/aYjp4tk4qf5za6tELoiEvA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Celgene's bowel disease treatment demonstrates efficacy in phase 2 trials

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Celgene's bowel disease treatment demonstrates efficacy in phase 2 trials

Celgene Corp. said its anti-inflammatory drug Ozanimod, or RPC1063, showed benefit in patients with Crohn's disease and ulcerative colitis.

In the phase 2 STEPSTONE study, 43% of the patients using Ozanimod saw a 25% decrease in Crohn's disease, while 27% of patients saw a reduction of 50% after 12 weeks.

In the phase 2 TOUCHSTONE study, 91% of ulcerative colitis patients at week 92 had little or no active disease. The most common adverse effects were ulcerative colitis flare, anemia, upper respiratory tract infection and back pain.

The results will be presented at the 2017 World Congress of Gastroenterology in Orlando, Fla.